Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers

References

• American Heart Association. Heart disease and stroke statistics: 2010 update. Available at: http://www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf [Last accessed 2 November 2010]
   Google Scholar
• Cengel A, Tanindi A. Myocardial infarction in the young. J Postgrad Med 2009;55:305-13
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007;17:6013-18
   PubMed Web of Science ®Google Scholar
• Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovas Ther 2009;27:259-74
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of opinion, Brilique, Sept 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001241/WC500100539.pdf [Last accessed 25 May 2011]
   Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195-204
   PubMed Web of Science ®Google Scholar
• Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug–drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 2011;39:703-10
   PubMed Web of Science ®Google Scholar
• Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-21
   PubMed Web of Science ®Google Scholar
• James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible, oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605
   PubMed Web of Science ®Google Scholar
• Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging? Menopause 2009;16:1021-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007;46:133-57
   PubMed Web of Science ®Google Scholar
• Thorne SA. Pregnancy in heart disease. Heart 2004;90:450-6
   PubMed Web of Science ®Google Scholar
• Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety and efficacy. Cutis 2008;81(Suppl 1);19-22
   PubMed Web of Science ®Google Scholar
• Wang B, Sanchesz RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethinyloestradiol. Drug Metab Dispos 2004;32:1209-12
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 1990;42:67-96
   PubMed Web of Science ®Google Scholar
• Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783-7
   PubMed Web of Science ®Google Scholar
• Hilbert J, Messig M, Kuye O, et al. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol 2001;98:218-23
   PubMed Web of Science ®Google Scholar
• Wong SL, O’Dea RF, Dube LM, et al. Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose ethinyl estradiol and levonorgestrel in healthy female volunteers. J Clin Pharmacol 1998;38:642-8
   PubMed Web of Science ®Google Scholar
• Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B 2010;878:2299-306
   PubMed Web of Science ®Google Scholar
• Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Phys 2007;76:391-6
   PubMed Web of Science ®Google Scholar
• Lawesson SS, Stenestrand U, Lagerqvist B, et al. Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction. Heart 2010;96:453-9
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Whitlock LA, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):19-26
   PubMed Web of Science ®Google Scholar
• Sidhu J, Job S, Singh S, et al. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006;61:191-9
   PubMed Web of Science ®Google Scholar
• Fotherby K. Levonorgrestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995;28:203-15
   PubMed Web of Science ®Google Scholar
• Hümpel M, Wendt H, Pommerenke G, et al. Investigations of pharmacokinetics of levonorgrestrel to specific consideration of a possible first-pass effect in women. Contraception 1978;17:207-20
   PubMed Web of Science ®Google Scholar
• Butler K, Teng, R. Pharmacokinetics, pharmacodynamics and safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Brit J Clin Pharmacol 2010;70:65-77
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6
   PubMed Web of Science ®Google Scholar
• Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3 A substrates. Clin Pharmacokinet 2005;44:33-60
   PubMed Web of Science ®Google Scholar
• Zhu B, Liu Z-Q, Chen G-L, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003;55:264-9
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mautz D, Senn T, et al. Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 1999;39:275-80
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kim MJ, Bertino JS, et al. Use of omeprazole as a CYP3A probe drug; effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. J Clin Pharmacol 2006;46:345-52
   PubMed Web of Science ®Google Scholar
• Teng, R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010;66:487-96
   PubMed Web of Science ®Google Scholar